Merck Solidifies RCC Position, While Bristol Gets Good SubQ Readout

Keytruda becomes the first immuno-oncology agent to show an overall survival benefit in adjuvant renal cell carcinoma. Bristol gains ground on Merck and Roche in race to develop a subcutaneous checkpoint inhibitor.